Eur Rev Med Pharmacol Sci 2018; 22 (2): 294-298
DOI: 10.26355/eurrev_201801_14171

MiR-599 as a potential biomarker for prognosis of glioma

X.-Y. Zhu, G.-X. Li, Z.-L. Liu

Department of Pathology, Department of Laboratory; Linyi People’s Hospital, Linyi, Shandong, China. lz777gl@126.com


OBJECTIVE: MicroRNAs (miRNAs) have been demonstrated to play a central role in development and progression in various cancers including glioma. This study aimed to determine the expression level of miRR-599 in glioma and to further investigate its clinical significance.

PATIENTS AND METHODS: The expression levels of miR-599 were evaluated in 184 paired of glioma and normal tissues by Real-time RT-PCR. The correlation between tumor miR-599 expression and the clinical and pathological features was analyzed using x2 test. Overall survival and progression-free survival curves were obtained using the Kaplan-Meier method. Cox regression analysis was conducted to analyze the prognostic value of miR-599.

RESULTS: We observed that miR-599 expression was significantly downregulated in glioma compared with the adjacent noncancerous tissues (p < 0.01). Correlation analysis revealed that miR-599 downregulation was significantly correlated with KPS (p = 0.000), WHO grade (p = 0.003) and recurrence (p = 0.039). Moreover, Kaplan-Meier analysis confirmed that low miR-599 expression was related to decreased and overall survival (p = 0.002) and progression-free survival (p = 0.001). Then, multivariate analysis revealed that miR-599 was an independent prognostic indicator for overall survival (p = 0.006) and progression-free survival (p = 0.003).

CONCLUSIONS: Our data, for the first time, demonstrated that miR-599 expression in glioma could be a useful prognostic marker.

Free PDF Download

To cite this article

X.-Y. Zhu, G.-X. Li, Z.-L. Liu
MiR-599 as a potential biomarker for prognosis of glioma

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 2
Pages: 294-298
DOI: 10.26355/eurrev_201801_14171